Gelesis Holdings, Inc.

Gelesis Holdings, Inc.

GLS-WT
Gelesis Holdings, Inc.US flagNew York Stock Exchange
0.01
USD
- -
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
Sector
Healthcare
Industry
Biotechnology
Address
Business
Gelesis Holdings, Inc. Gelesis Holdings, Inc. (GLS-WT) operates as a biotherapeutics company that develops superabsorbent hydrogel therapeutics for chronic gastrointestinal diseases, including obesity, type 2 diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, functional constipation, and inflammatory bowel disease; its flagship product Plenity serves as an FDA-cleared, orally administered, non-stimulant, non-systemic weight management aid inspired by the properties of raw vegetables that expands in the stomach to promote satiety; the company also advances GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and preclinical GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Founded in 2006 and headquartered in Boston, Massachusetts, Gelesis primarily targets overweight and obese adults as well as patients with related metabolic conditions through prescription-based consumer engagement in the United States and select international markets. In October 2023, the company, along with affiliates Gelesis, Inc. and Gelesis LLC, filed voluntary petitions for Chapter 7 liquidation in the U.S. Bankruptcy Court for the District of Delaware due to funding shortfalls following its 2022 SPAC merger and halted marketing efforts; in July 2024, the Chapter 7 trustee completed the sale of substantially all assets, including intellectual property and majority equity in an Italian manufacturing affiliate, to T-Investments S.r.l. and Andromeda Energy S.r.l.